CNNMoney.com
Companies Economy International Corrections Pre-market Trading After-hours Trading Winners/Losers/Actives Bonds Currencies Commodities World Markets Money Magazine Real Estate Taxes Jobs Ask the Expert Money 101 Autos Mutual Funds The Help Desk Loan Center Best Places to Live Ask the Expert Ultimate Guide to Retirement Retirement Calculators Best Funds Best Places to Retire Fortune Brainstorm Tech Apple 2.0 Blog Big Tech Blog Sectors and Stocks Tech Talk Resource Guide Small Business Makeovers Questions & Answers Small Business Video 100 Best Places to Launch FSB 100 Fortune Small Business Fortune 500 Brainstorm Tech Investing Management C-Suite Rankings Main Create Portfolio Edit Portfolio Create Alerts Edit Alerts

U.S.: More data on Merck-Schering merger

Drugmakers still see deal closing in fourth quarter, despite second request from Federal Trade Commission.

EMAIL  |   PRINT  |   SHARE  |   RSS
 
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)

What investment strategy will you follow for the rest of the year?
  • Aggressively buying stocks
  • Slowly adding more stocks
  • Beefing up bonds and cash
  • Not changing a thing

NEW YORK (Reuters) -- Drugmakers Merck & Co. and Schering-Plough Corp. have received requests from U.S. antitrust regulators for more information on their proposed blockbuster merger.

Despite the second request from the Federal Trade Commission, the companies said on Monday they still expect the deal to close in the fourth quarter.

A Schering-Plough spokesman said the FTC request was primarily related to the companies' animal health businesses. Merck previously said it was exploring divesting its stake in its animal health venture with Sanofi-Aventis (SNY) or selling a similar unit at Schering as part of the planned merger.

The companies said they had anticipated the FTC request and would cooperate fully.

Merck's (MRK, Fortune 500) acquisition of Schering (SGP, Fortune 500), pegged at $41.1 billion when it was announced in March, would unite the makers of the cholesterol drugs Zetia and Vytorin.

Linda Bannister, a pharmaceutical analyst at Edward Jones, said she was "not overly concerned" about antitrust obstacles to the deal.

"I think the issue is related to the animal health business specifically," Bannister said. "I think there are plenty of other big pharma companies that are willing to take a look at those assets."

She added, "I would be surprised if the merger doesn't close as planned."

Merck shares were down 49 cents, or 1.9%, to $25.42 in morning trading on the New York Stock Exchange. Schering was off 23 cents, or 1%, at $23.57, also on the NYSE. To top of page

Features
Markets Last Change
Dow Jones 10,226.94 203.52 / 2.03%
Nasdaq 2,154.06 41.62 / 1.97%
S&P 500 1,093.08 23.78 / 2.22%
10-year Bond 101 4/32 Yield: 3.48%
U.S.Dollar 1 euro = $1.499 -0.001
November 9, 2009 4:03 PM ET
CompanyPrice% Change
Sprint Nextel Corp 3.28 15.09%
Radioshack Corp 20.23 14.04%
TRW Automotive Holdings Corp 22.95 11.46%
Unisys Corp 33.82 9.13%
Nov 9 3:53pm ET †
More Galleries
What I bought with my $8,000 tax credit These 7 new homeowners stepped up their house-hunting to take advantage of the first-time buyer tax credit. More
Then and now: 'The worst slum in America' Charlotte Street in New York City's South Bronx was once world famous for its blight. Now it's a slice of suburbia in the inner city - complete with Beemers and boats. More
Hope for homeowners Critics thought homeownership would never work in the South Bronx. They were wrong. Tour the one house currently for sale on Charlotte Street. More
Sponsors

Copyright 2009 Reuters All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
© 2009 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy
Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.